INTRODUCTION
============

Aspirin is used for the prevention of cardiovascular and cere-brovascular diseases worldwide. However, aspirin is also known to have adverse effects on the gastrointestinal (GI) tract including peptic ulcer disease and bleeding. The annual incidence of peptic ulcers induced by aspirin is approximately 5% to 10%,[@b1-gnl-10-362]--[@b3-gnl-10-362] and the prevalence is approximately 10%.[@b2-gnl-10-362] The presence of peptic ulcers can induce a number of serious adverse effects including GI bleeding that may result in death in some patients.[@b4-gnl-10-362]

There are a number of risk factors for the development of peptic ulcers secondary to aspirin use including advanced age, *Helicobacter pylori* infection, concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin dose, and a past medical history of peptic ulcers.[@b2-gnl-10-362],[@b5-gnl-10-362] Additionally, genetic predisposition is also associated with aspirin-induced peptic ulcer.[@b6-gnl-10-362]--[@b8-gnl-10-362] In order to prevent peptic ulcer in patients taking low-dose aspirin, concomitant use of a proton pump inhibitor is often initiated. However, this strategy does not help to identify patients with a high risk of developing peptic ulcers. Therefore, individual genetic susceptibility may be an important factor in identifying patients at highest risk for peptic ulcer.

Several studies have shown an association between single nucleotide polymorphisms (SNPs) of several genes and aspirin-induced peptic ulcer. These include SNPS of the *COX-1*, *CY-P2C9*, *IL-1β*, *IL-1RN*, and *TNF-α* genes.[@b9-gnl-10-362] However, there is racial diversity in these genes, and thus the significance of SNPs as related to specific diseases is also different among races.

We hypothesized that, if patients could be identified as having a genetic predisposition for peptic ulcer before starting aspirin therapy, the development of peptic ulcer could be prevented by concomitant use of proton pump inhibitors or alternative antiplatelet agents. Because SNPs of the *COX-1*, *IL-1β*, *IL-1RN*, *TNF* genes, and SNPs specifically associated with peptic ulcer are still not well understood, we investigated the prevalence of SNPs of the *COX-1*, *IL-1β*, *IL-1RN*, and *TNF* genes in Korean adults and evaluated the associations between these SNPs and aspirin-induced peptic ulcer in this population, as a pilot research.

MATERIALS AND METHODS
=====================

1. Subjects
-----------

From May 2011 to December 2012, we performed a prospective case-control study of DNA sequence analysis on 48 patients who took low-dose aspirin and underwent esophagogastroduodenoscopy (EGD). All subjects had been taking low-dose aspirin (100 mg) for at least 4 weeks prior to enrollment, and each subsequently underwent EGD at Myongji Hospital in Goyang, Korea. They were divided into two groups based on endoscopy results including a nonulcer control group (n=25) with no evidence of peptic ulcer and a peptic ulcer group (n=23) that showed evidence of gastric or duodenal ulcer. In this study, a peptic ulcer was defined as a mucosal defect ≥5 mm in diameter based on endoscopic findings. Exclusion criteria included history of peptic ulcer, history of NSAID or steroid use, history of clopidogrel use, history of upper GI surgery, pregnancy, chronic renal failure, history of proton pump inhibitor or H~2~ receptor blocker use, history of congenital disease, history of autoimmune disease, and malignant disease of the upper GI tract including esophageal or gastric cancer. Blood obtained from subjects was stored in ethylenediaminetetraacetic acid-containing tubes at −40°C and was subsequently sent to a laboratory facility for genotyping. SNP data were compared between groups. Informed consent was obtained from all subjects. This study was approved by the Institutional Review Board (IRB number: 10--076) at Myongji Hospital and all patients gave written informed consent to participate in this study.

2. DNA sequencing
-----------------

Polymerase chain reaction (PCR) was used to amplify 11 fragments of the *IL-1β* gene, 10 fragments of the *IL-1RN* gene, 15 fragments of the *COX-1* gene, and eight fragments of the *TNF* gene. The final volume of the PCR was 10 μL, consisting of 10 ng of DNA, 0.5 uM of each primer pair, 0.25 mM deoxy-ribonucleoside triphosphates, 3 mM MgCl~2~, 1 μL 1× reaction buffer, and 0.25 unit Taq DNA polymerase (Intron Biotechnology, Seongnam, Korea). The PCR conditions used were as follows: initial denaturation at 94°C for 5 minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C to 65°C for 30 seconds, initial extension at 72°C for 30 to 60 seconds, and final extension at 72°C for 10 minutes. The PCR products were purified using a MultiScreen 384-PCR filter plate (Millipore, Billerica, MA, USA). The purified products were then sequenced using a BigDye Terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI 3730xl automated sequencer (Applied Biosystems). The sequencing primers were the same as those used for PCR amplification. Mutation analyses were performed using Phred, Phrap, Consed, Polyphred 5.04 software (<http://droog.gs.washington.edu/polyphred>).

3. Statistical analysis
-----------------------

Genotype and allele frequencies were compared between groups using chi-square or Jonckheere-Terpstra test, as appropriate. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multiple logistic regression with adjustments for age and sex in order to evaluate the significance of the associations between SNPs and disease status. Data analysis was performed using SAS software version 9.1.3 (SAS Inc., Cary, NC, USA). All statistical tests were two-tailed, and p-values \<0.05 were considered to be statistically significant.

RESULTS
=======

1. Baseline characteristics
---------------------------

Between January 2011 and January 2013, a total of 48 patients were enrolled in this study, including 23 subjects with peptic ulcer and 25 nonulcer control subjects ([Table 1](#t1-gnl-10-362){ref-type="table"}). The mean ages of the peptic ulcer group and nonulcer control group were 66.22±10.85 years and 62.48±9.01 years, respectively (p=0.199). The percentages of male patients in the peptic ulcer group and nonulcer control group were 60.9% and 48%, respectively (p=0.371). On EGD examination, peptic ulcers were found to be located in the stomach (91.3%) and duodenum (8.7%). Thirteen patients (56.5%) had a single ulcer and 10 patients (43.5%) had multiple ulcers (≥2).

2. SNPs of the *COX-1*, *IL-1β*, *IL-1RN*, and *TNF* genes
----------------------------------------------------------

All SNPs of the four genes identified in this study are shown in [Table 2](#t2-gnl-10-362){ref-type="table"}. The *IL-1RN* gene had 31 SNPs, of which two (-1126G/T and 554G/A) were newly identified. The *IL-1β* gene had 22 SNPs, of which 9 (-2369G/A, -2091\~-2088CT/CTCTDEL, IVS3-25G/A, G46G, IVS4-509T/C, -1468G/C, -625T/G, E101E, and IVS5+204G/A) were newly identified. The *COX-1* gene had 23 SNPs, of which 11 (-1837G/T, -1622G/A, -1337A/G, -1336A/C, IVS7+145G/A, and IVS8+136C/T) were newly identified. The *TNF* gene had 12 identified SNPs.

3. Associations between SNPs and peptic ulcer
---------------------------------------------

Four SNPs had significantly different frequencies in the peptic ulcer and nonulcer control groups: *IL-1RN* -1129C/T (rs4251961), *IL-1β* -581C/T (rs1143627), *IL-1β* -1061C/T (rs16944), and *IL-1β* IVS2+242C/T (rs1143629). For *IL-1β* -581C/T, the TT genotype was less frequent in the peptic ulcer group than the nonulcer control group (13% vs 44%, p=0.018) ([Table 3](#t3-gnl-10-362){ref-type="table"}). For *IL-1β* -1061C/T, the CC genotype was less frequent in the peptic ulcer group than the nonulcer control group (13% vs 44%, p=0.018). For *IL-1β* IVS2+242C/T, the TT genotype was less frequent in the peptic ulcer group than the nonulcer control group (13% vs 44%, p=0.018). Finally, for *IL-1RN* -1129C/T, the TT genotype was more frequent in the peptic ulcer group than the nonulcer control group (96% vs 68%, p=0.011).

Logistic regression analysis for adjustment of age and sex was performed in three exon SNPs ([Table 4](#t4-gnl-10-362){ref-type="table"}). The *IL-1β* -581 genotype was significantly associated with peptic ulcer. The CT and CC genotype had an OR of 4.625 (95% CI, 1.054 to 20.303; p=0.042) for the peptic ulcer group, as compared with the TT genotype. The *IL-1β* -1061 genotype was also significantly associated with peptic ulcer, and the CT and TT genotypes had an OR of 4.625 (95% CI, 1.054 to 20.303; p=0.042) for the peptic ulcer groups compared with the CC genotype. The *IL-1RN* -1129 genotype was not associated with peptic ulcer after adjustment for age and gender. The CT and CC genotypes had an OR of 0.115 (95% CI, 0.013 to 1.049; p=0.055) for the peptic ulcer group.

DISCUSSION
==========

Our study is the first to investigate SNPs of the *COX-1*, *IL-1β*, *IL-1RN*, and *TNF* genes in Korean subjects, identifying 23, 22, 31, and 12 SNPs, respectively, including 22 novel SNPs. In addition, we aimed to reveal the significant associations between specific genotypes and aspirin-induced peptic ulcer disease. Of a total of 88 SNPs, two of the *IL-1β* gene and one of the *IL-1RN* gene were significantly associated with peptic ulcer. C carriers of *IL-1β* -581 and T carriers of *IL-1β* -1061 were significantly more frequently associated with peptic ulcer, and there was a trend for association between T carriers of *IL-1RN* -1129 and peptic ulcer, though this was not significant after adjustment for age and sex.

Aspirin irreversibly inhibits cyclooxygenase-1 (*COX-1*) in platelets. Genetic polymorphisms of the *COX-1* gene can affect aspirin-induced inhibition of prostaglandin synthesis, which eventually can result in the development of peptic ulcer. Several SNPs of the *COX-1* gene are known to have a significant relationship with peptic ulcer.[@b7-gnl-10-362],[@b10-gnl-10-362] In U.S. study, two SNPs of *COX-1*, A-842G and C50T, were found to be associated with aspirin-induced peptic ulcer.[@b7-gnl-10-362] The heterozygous A-842G/C50T haplotype inhibits prostaglandin synthesis by acetylsalicylic acid to a greater degree than does the homozygous haplotype.[@b7-gnl-10-362] However, the opposite results have also been reported for A-842G/C50T.[@b11-gnl-10-362],[@b12-gnl-10-362] A recent systematic review shows no significant association between these SNPs and aspirin resistance.[@b13-gnl-10-362] In addition, different results have been obtained in patients of other races. In Japanese study, the A-842T/C50T polymorphism of the *COX-1* gene was not detected in any of the 480 patients studied.[@b6-gnl-10-362] Similarly, this polymorphism was absent in 323 Chinese subjects.[@b14-gnl-10-362] Variable results have been reported within races as well. One study in a Japanese population reported that -1676T alleles of the *COX-1* gene promoter were a significant risk factor for NSAID-induced ulcers,[@b6-gnl-10-362] while another Japanese study reported that -1676T alleles are not associated with aspirin-induced peptic ulcer.[@b8-gnl-10-362] In our study, a total of 23 SNPs of the *COX-1* gene were found, none of which were associated with aspirin-induced peptic ulcer.

The biological role of *IL-1β* is to enhance the inflammatory response, and the cytokine *IL-1β* induces the expression of other proinflammatory cytokine genes including *TNF-α*, *IL-2*, *IL-6*, and *IL-12*.[@b15-gnl-10-362] In addition, *IL-1β* is an inhibitor of gastric acid.[@b15-gnl-10-362] Polymorphisms of *IL-1β* -511 (rs16944) and -31 (rs1143627) have been shown to be significantly associated with aspirin-induced peptic ulcer in Japanese patients.[@b8-gnl-10-362] These findings are consistent with those of our study, in which *IL-1β* -1061T (rs16944), which is the same SNP as *IL-1β* -511, was significantly associated with aspirin-induced peptic ulcer. In addition, *IL-1β* -581C (rs1143627), which is the same as *IL-1β* -31, was significantly associated with aspirin-induced peptic ulcer. T carriers of *IL-1β* -511 have an associated increased production of *IL-1β*, which enhances inflammation of the gastric mucosa.[@b9-gnl-10-362],[@b16-gnl-10-362] In our study, T carriers of *IL-1β* -1061 (*IL-1β* -511) had a 4.6-fold increased risk of low-dose aspirin-induced peptic ulcer. In the future, screening for SNPs of *IL-1β* prior to initiating aspirin therapy could help to identify patients at high risk for ulcer development and bleeding. These individuals should also be administered a prophylactic proton pump inhibitor, although this assumption requires further investigation.

The *IL-1RN* gene encodes the IL-1R antagonist (IL-1RA), which exhibits anti-inflammatory properties by competitive inhibition of IL-1 receptors.[@b16-gnl-10-362],[@b17-gnl-10-362] One study reported that the minor allele of *IL-1RN* -1129 (rs4251961) is associated with decreased IL-1RA production in healthy adults.[@b17-gnl-10-362] The C allele of *IL-1RN* -1129 reduces IL-1RA, which is associated with an increased *IL-1β* level that in turn inhibits gastric acid secretion.[@b18-gnl-10-362] These findings are consistent with our results, in that the TT genotype of *IL-1RN* -1129 was found in 95.7% of patients with peptic ulcer, although this was not statistically significant after adjustment for age and sex. Further investigation of *IL-1RN* -1129 as a potential risk factor for low-dose aspirin-induced peptic ulcer would be valuable.

Our study has several limitations. First, our sample size was too small and thus may not be representative of general genetic trends in the Korean population. In order to find the associations between SNPs and low dose aspirin induced peptic ulcer, we performed the full DNA sequence analysis of these target genes and proposed the several candidates of SNPs related to aspirin induced ulcer. Second, the functional effect of these SNPs are still doubtful. The functional consequences of *IL-1β* -581C/T (rs1143627) and *IL-1β* -1061C/T (rs16944) are known to the "upstream variant 2KB" ([Table 3](#t3-gnl-10-362){ref-type="table"}). There is a possibility that they may affect the promoter activity by the differential binding affinity of nuclear proteins, however pathogenic effect of them has not yet been established. Third, the presence of *H. pylori* is questionable in this study. One previous study reported that *H. pylori* infection does not affect peptic ulcer induced by low-dose aspirin;[@b19-gnl-10-362] however, *H. pylori* is regarded as a major cause of peptic ulcer disease and account for a large proportion of peptic ulcers in Korea. Therefore, further investigation including *H. pylori* infection and a functional assay for these SNPs are warranted. Even with these noted limitations, however, this study is the first to investigate the relationships between SNPs and aspirin-induced peptic ulcer in Korean patients, as well as the first to suggest that SNPs may be different according to the population studied.

In conclusion, Korean adults with the the C allele of *IL-1β* -581C/T or the T allele of *IL-1β* -1061C/T had an increased risk of low-dose aspirin-induced peptic ulcer. The polymorphism *IL-1RN* -1129 might also be associated with peptic ulcer, although this trend was not significant. These SNPs may become potential biomarkers for identifying patients at high risk for aspirin-induced peptic ulcer, although further investigation and validation are needed.
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###### 

Baseline Characteristics of All Subjects (n=48)

  Characteristic                    Peptic ulcer   Nonulcer control   p-value
  --------------------------------- -------------- ------------------ ---------
  No. of patients                   23 (47.9)      25 (52.1)          \-
  Age, yr                           66.22±10.85    62.48±9.01         0.199
  Sex, male/female                  14/9           12/13              0.371
  Ulcer location                                                      \-
   Gastric ulcer                    21 (91.3)      \-                 \-
    Active or healing stage         18             \-                 
    Scar                            5              \-                 
   Duodenal ulcer                   2 (8.7)        \-                 \-
    Active or healing stage         1              \-                 
    Scar                            1              \-                 
  Multiple ulcer (≥2)               10 (43.5)      \-                 \-
  *Helicobacter pylori* infection   6 (26.1)       \-                 \-

Data are presented as number (%) or mean±SD.

###### 

Single Nucleotide Polymorphisms of *IL-1RN, IL-1β, COX-1*, and *TNF*

       *IL-1RN*     *IL-1β*       *COX-1*                             *TNF*                                                                       
  ---- ------------ ------------- ----------------------------------- ------------------------ ------------ ------------- ----------------------- -------------
  1    New          -1126G/T      New                                 -2369G/A                 New          -1837G/T      rs13306710              IVS3+104A/G
  2    New          554G/A        New                                 -2091\~-2088CT/CTCTDEL   New          -1622G/A      rs1799724               -1037C/T
  3    rs11677397   -515C/T       New                                 IVS3-25G/A               New          -1337A/G      rs1799964               -1211C/T
  4    rs16065      IVS1+26C/T    New                                 G46G                     New          -1336A/C      rs1800610, rs80267959   IVS1+123A/G
  5    rs17042923   -206C/T       New                                 IVS4-509T/C              New          IVS7+145G/A   rs1800629               -488A/G
  6    rs2232354    IVS4+94G/T    New                                 -1468G/C                 New          IVS8+136C/T   rs1800630, rs4645836    -1043A/C
  7    rs2234676    -168A/G       New                                 -625T/G                  New          -2084G/C      rs3093547               -1671A/T
  8    rs2234677    -87A/G        New                                 E101E                    New          -1266G/A      rs3093661, rs77222141   IVS1+54A/G
  9    rs2234678    -31A/G        New                                 IVS5+204G/A              New          IVS3+265T/A   rs3093664               IVS3+51A/G
  10   rs2234679    -12C/G        rs1143623                           -2023C/G                 New          IVS4+52T/C    rs361525                -418A/G
  11   rs315951     681C/G        rs1143625                           -1553A/G                 New          A526S         rs4248160               -826A/G
  12   rs315952     S133S         rs1143627                           -581C/T                  rs10306117   IVS2+177C/T   rs4248161               -752A/C
  13   rs380092     IVS5+166A/T   rs1143629                           IVS2+242C/T              rs10306227   IVS3+206A/G   \-                      \-
  14   rs419598     A60A          rs1143633                           IVS4-64A/G               rs1236913    R8W           \-                      \-
  15   rs423904     IVS4+21C/T    rs1143634                           F105F                    rs12555242   IVS5+42C/T    \-                      \-
  16   rs4251961    -1129C/T      rs1143639                           IVS6+76A/G               rs1330344    -1676C/T      \-                      \-
  17   rs4251967    -628C/G       rs1143640, rs34159283, rs41294738   IVS6+111\~+113T/TTTDEL   rs2282169    IVS3-16C/G    \-                      \-
  18   rs4251968    -379A/C       rs1143643                           IVS6-152A/G              rs3215925    IVS7+14-/A    \-                      \-
  19   rs4251986    IVS1-105C/G   rs16944                             -1061C/T                 rs3842788    Q41Q          \-                      \-
  20   rs4252013    IVS4+132C/T   rs3917347                           -400\~-385CT/-DEL        rs3842798    IVS7-45C/T    \-                      \-
  21   rs432014     IVS4-43C/T    \-                                  \-                       rs5788       G213G         \-                      \-
  22   rs442710     IVS4+158A/G   \-                                  \-                       rs61757787   D248G         \-                      \-
  23   rs446433     IVS4+32A/G    \-                                  \-                       rs6478565    IVS8-93A/G    \-                      \-
  24   rs451578     IVS4-65A/G    \-                                  \-                       \-           \-            \-                      \-
  25   rs454078     IVS5+59A/T    \-                                  \-                       \-           \-            \-                      \-
  26   rs45462902   -1022A/G      \-                                  \-                       \-           \-            \-                      \-
  27   rs45507693   T127A         \-                                  \-                       \-           \-            \-                      \-
  28   rs495282     IVS4+53C/G    \-                                  \-                       \-           \-            \-                      \-
  29   rs495410     IVS4+97A/C    \-                                  \-                       \-           \-            \-                      \-
  30   rs878972     IVS2+8A/C     \-                                  \-                       \-           \-            \-                      \-
  31   rs928940     IVS1-148G/T   \-                                  \-                       \-           \-            \-                      \-

SNP, single nucleotide polymorphism.

###### 

Single Nucleotide Polymorphism Genotypes in the Peptic Ulcer Group and Nonulcer Control Group

  SNP                   SNP ID      MAF      Peptic ulcer (n=23)   Nonulcer control (n=25)   p-value                                             Functional consequence
  --------------------- ----------- -------- --------------------- ------------------------- --------------------------------------------------- ------------------------
  *IL-1β* -581C/T       rs1143627   0.4479                                                   0.0184[\*](#tfn5-gnl-10-362){ref-type="table-fn"}   Upstream variant 2KB
   TT                                        3 (13.04)             11 (44.0)                                                                     
   CT                                        15 (65.22)            10 (40.0)                                                                     
   CC                                        5 (21.74)             4 (16.0)                                                                      
  *IL-1β* -1061C/T      rs16944     0.4479                                                   0.0184[\*](#tfn5-gnl-10-362){ref-type="table-fn"}   Upstream variant 2KB
   CC                                        3 (13.04)             11 (44.0)                                                                     
   CT                                        15 (65.22)            10 (40.0)                                                                     
   TT                                        5 (21.74)             4 (16.0)                                                                      
  *IL-1β* IVS2+242C/T   rs1143629   0.4583                                                   0.0184[\*](#tfn5-gnl-10-362){ref-type="table-fn"}   Intron variant
   TT                                        3 (13.04)             11 (44.0)                                                                     
   CT                                        15 (65.22)            9 (36.0)                                                                      
   CC                                        5 (21.74)             5 (20.0)                                                                      
  *IL-1RN* -1129C/T     rs4251961   0.1042                                                   0.0116[†](#tfn6-gnl-10-362){ref-type="table-fn"}    Upstream variant 2KB
   TT                                        22 (95.7)             17 (68.0)                                                                     
   CT                                        1 (14.4)              7 (28.0)                                                                      
   CC                                        0                     1 (4.0)                                                                       

Data are presented as number (%).

SNP, single nucleotide polymorphism; MAF, minor allele frequency.

Chi-square test with dominant model;

Jonckheere-Terpstra test with allele model.

###### 

Odds Ratios of Genotypes in the Peptic Ulcer Group (n=23) and Nonulcer Control Group (n=25)

  SNP                 SNP ID      Unadjusted              Adjusted[\*](#tfn8-gnl-10-362){ref-type="table-fn"}                           
  ------------------- ----------- ----------------------- ----------------------------------------------------- ----------------------- -------
  *IL-1β* -581C/T     rs1143627                                                                                                         
   TT                             1                                                                             1                       
   CT                             5.5 (1.219--24.813)     0.022                                                 4.999 (1.068--23.394)   0.040
   CC                             4.583 (0.733--28.646)   0.100                                                 4.297 (0.653--28.285)   0.129
   TT (dominant)                  1                                                                             1                       
   CT and CC                      5.238 (1.231--22.282)   0.024                                                 4.625 (1.054--20.303)   0.042
  *IL-1β* -1061C/T    rs16944                                                                                                           
   CC                             1                                                                             1                       
   CT                             5.5 (1.219--24.813)     0.022                                                 4.999 (1.068--23.394)   0.040
   TT                             4.583 (0.733--28.646)   0.100                                                 4.297 (0.653--28.285)   0.129
   CC (dominant)                  1                                                                             1                       
   CT and TT                      5.238 (1.231--22.282)   0.024                                                 4.625 (1.054--20.303)   0.042
  *IL-1RN* -1129C/T   rs4251961                                                                                                         
   TT                             1                                                                             1                       
   CT                             0.11 (0.012--0.985)     0.025                                                 0.135 (0.014--1.272)    0.080
   CC                             \-                                                                            \-                      
   TT (dominant)                  1                                                                             1                       
   CT and CC                      0.097 (0.011--0.849)    0.035                                                 0.115 (0.013--1.049)    0.055

SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

Logistic regression analysis was applied to adjust age and sex.
